Research work · 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri, Peter Reichardt, Yoon‐Koo Kang, Jean‐Yves Blay, Piotr Lukasz Rutkowski, Hans A. J. Gelderblom, Peter Hohenberger, Michael Gordon Leahy, Margaret von Mehren, Heikki Joensuu, Giuseppe Badalamenti, Martin E. Blackstein, Axel Le Cesne, Patrick Schöffski, Robert G. Maki, Sebastian Bauer, Binh Bui Nguyen, Jianming Xu, Toshirou Nishida, John Chung
The Lancet